STOCK TITAN

Christopher Gibson (RXRX) logs conversions, sales and RSU vesting in Form 4

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Recursion Pharmaceuticals director Christopher Gibson reported several stock transactions in early February 2026. On February 4, he converted 40,000 shares of Class B Common Stock into Class A at $0 per share, then sold 40,000 Class A shares at $4.12 under a pre-arranged Rule 10b5-1 trading plan.

On February 6, Gibson received 30,346 Class A shares from restricted stock units that vested immediately at $0, and 10,364 shares were withheld at $3.56 to cover taxes. After these transactions, he directly held 933,821 Class A shares, alongside sizable option and convertible Class B positions.

Positive

  • None.

Negative

  • None.
Insider Gibson Christopher
Role Director
Sold 40,000 shs ($165K)
Type Security Shares Price Value
Grant/Award Class A Common Stock 30,346 $0.00 --
Tax Withholding Class A Common Stock 10,364 $3.56 $37K
Conversion Class B Common Stock 40,000 $0.00 --
Conversion Class A Common Stock 40,000 $0.00 --
Sale Class A Common Stock 40,000 $4.12 $165K
holding Class B Common Stock -- -- --
holding Class B Common Stock -- -- --
holding Class B Common Stock -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
Holdings After Transaction: Class A Common Stock — 944,185 shares (Direct); Class B Common Stock — 4,583,334 shares (Direct); Class B Common Stock — 0 shares (Indirect, by LAHWRAN-3 LLC); Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
  1. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. This RSU vested immediately upon the grant date. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gibson Christopher

(Last) (First) (Middle)
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET

(Street)
SALT LAKE CITY UT 84101

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 02/04/2026 C(1)(2) 40,000 A $0 953,839 D
Class A Common Stock 02/04/2026 S(2) 40,000 D $4.12 913,839 D
Class A Common Stock 02/06/2026 A(3) 30,346 A $0 944,185 D
Class A Common Stock 02/06/2026 F(4) 10,364 D $3.56 933,821 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Common Stock $0(1) 02/04/2026 C 40,000 (1) (1) Class A Common Stock 40,000 $0 4,583,334 D
Class B Common Stock $0 (1) (1) Class A Common Stock 0 386,000 I by LAHWRAN-3 LLC(5)
Class B Common Stock $0 (1) (1) Class A Common Stock 0 388,000 I by LAHWRAN-4 LLC(6)
Class B Common Stock $0 (1) (1) Class A Common Stock 0 50,000 I by Gibson Family Trust(7)
Stock Option (Right to Buy) $7.25 (8) 02/03/2035 Class A Common Stock 0 1,050,567 D
Stock Option (Right to Buy) $10.09 (9) 02/09/2034 Class A Common Stock 0 666,898 D
Stock Option (Right to Buy) $8.55 (10) 02/01/2033 Class A Common Stock 0 813,600 D
Stock Option (Right to Buy) $11.4 (11) 02/04/2032 Class A Common Stock 0 399,002 D
Stock Option (Right to Buy) $11.4 02/04/2022 02/04/2032 Class A Common Stock 0 5,436 D
Stock Option (Right to Buy) $2.48 (12) 12/30/2030 Class A Common Stock 0 282,500 D
Explanation of Responses:
1. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
3. This RSU vested immediately upon the grant date.
4. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
5. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
6. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
7. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
9. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
10. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
11. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
12. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Remarks:
/s/ Kyle Nelson, attorney-in-fact 02/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Christopher Gibson report for RXRX in February 2026?

Christopher Gibson reported converting 40,000 Class B shares to Class A, selling 40,000 Class A shares at $4.12, receiving 30,346 Class A shares from vested RSUs, and having 10,364 shares withheld for taxes, all in early February 2026.

How many Recursion Pharmaceuticals (RXRX) shares does Christopher Gibson hold after these transactions?

After the reported transactions, Christopher Gibson directly holds 933,821 shares of Recursion Pharmaceuticals Class A Common Stock. He also has interests in convertible Class B shares and multiple stock options that provide additional potential exposure to Class A shares.

Were Christopher Gibson’s February 2026 RXRX stock sales pre-planned?

Yes. The Form 4 states that the February 4, 2026 sale of 40,000 Class A shares at $4.12 occurred under a Rule 10b5-1 trading plan that Gibson adopted on May 12, 2025, indicating the sale followed a pre-established trading program.

What was the price and size of Christopher Gibson’s February 4, 2026 RXRX share sale?

On February 4, 2026, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock at a price of $4.12 per share. This sale followed a same-day conversion of 40,000 Class B shares into Class A at $0 per share.